Target Price | €185.27 |
Price | €141.75 |
Potential | 30.70% |
Number of Estimates | 15 |
15 Analysts have issued a price target Merck 2025 . The average Merck target price is €185.27. This is 30.70% higher than the current stock price. The highest price target is €200.00 41.09% , the lowest is €160.00 12.87% . | |
A rating was issued by 17 analysts: 14 Analysts recommend Merck to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2025 of 30.70% . Most analysts recommend the Merck stock at Purchase. |
14 Analysts have issued a sales forecast Merck 2024 . The average Merck sales estimate is €21.1b . This is 1.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €21.3b 2.13% , the lowest is €21.0b 0.49% .
This results in the following potential growth metrics:
2023 | €21.0b | 5.57% |
---|---|---|
2024 | €21.1b | 0.68% |
2025 | €22.1b | 4.37% |
2026 | €23.1b | 4.51% |
2027 | €24.1b | 4.36% |
2028 | €25.1b | 4.30% |
14 Analysts have issued an Merck EBITDA forecast 2024. The average Merck EBITDA estimate is €6.0b . This is 2.81% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.1b 1.22% , the lowest is €5.8b 6.30% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | €5.8b | 15.15% |
---|---|---|
2024 | €6.0b | 3.63% |
2025 | €6.5b | 8.22% |
2026 | €7.0b | 6.96% |
2027 | €7.3b | 4.74% |
2028 | €7.8b | 6.33% |
2023 | 27.75% | 10.14% |
---|---|---|
2024 | 28.56% | 2.93% |
2025 | 29.61% | 3.68% |
2026 | 30.31% | 2.36% |
2027 | 30.42% | 0.36% |
2028 | 31.01% | 1.94% |
12 Merck Analysts have issued a net profit forecast 2024. The average Merck net profit estimate is €2.9b . This is 11.00% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.1b 19.21% , the lowest is €2.8b 7.12% .
This results in the following potential growth metrics and future Net Margins:
2023 | €2.8b | 15.03% |
---|---|---|
2024 | €2.9b | 3.15% |
2025 | €3.4b | 17.04% |
2026 | €3.7b | 9.63% |
2027 | €4.0b | 7.84% |
2028 | €4.4b | 8.61% |
2023 | 13.46% | 10.02% |
---|---|---|
2024 | 13.79% | 2.44% |
2025 | 15.47% | 12.18% |
2026 | 16.22% | 4.85% |
2027 | 16.77% | 3.39% |
2028 | 17.46% | 4.11% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €6.70 . This is 10.93% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €7.20 19.21% , the lowest is €6.47 7.12% .
This results in the following potential growth metrics and future valuations:
2023 | €6.50 | 15.03% |
---|---|---|
2024 | €6.70 | 3.08% |
2025 | €7.85 | 17.16% |
2026 | €8.60 | 9.55% |
2027 | €9.28 | 7.91% |
2028 | €10.08 | 8.62% |
Current | 23.47 | 0.47% |
---|---|---|
2024 | 21.14 | 9.93% |
2025 | 18.06 | 14.57% |
2026 | 16.48 | 8.75% |
2027 | 15.28 | 7.28% |
2028 | 14.07 | 7.92% |
Based on analysts' sales estimates for 2024, the Merck stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.30 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.92 .
This results in the following potential growth metrics and future valuations:
Current | 3.34 | 6.96% |
---|---|---|
2024 | 3.30 | 1.33% |
2025 | 3.16 | 4.18% |
2026 | 3.02 | 4.31% |
2027 | 2.90 | 4.18% |
2028 | 2.78 | 4.12% |
Current | 2.95 | 7.27% |
---|---|---|
2024 | 2.92 | 1.26% |
2025 | 2.79 | 4.18% |
2026 | 2.67 | 4.31% |
2027 | 2.56 | 4.17% |
2028 | 2.46 | 4.12% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.